Esperion Therapeutics (ESPR) Tops Q3 EPS by 5c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.77), $0.05 better than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Can the bull market survive surging oil prices & bond yields?
• BofA sees just 2% upside for the S&P 500 over the next 12 months
• Perdoceo to acquire South University for up to $204M